Bioventus (BVS) Other Accumulated Expenses (2020 - 2026)

Bioventus (BVS) has 7 years of Other Accumulated Expenses data on file, last reported at $4.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 4.57% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (down 4.57% YoY) and the FY2025 annual result came in at $4.2 million, up 7.48% from the prior year.
• Other Accumulated Expenses slipped to $4.2 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.8 million in Q4 2023 to a low of $3.5 million in Q4 2022.
• A 5-year average of $4.2 million and a median of $4.2 million in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses slumped 61.36% — and 2023, when it jumped 35.38%.
• Tracing BVS's Other Accumulated Expenses over 5 years: stood at $3.6 million in 2022, then surged by 33.52% to $4.8 million in 2023, then slipped by 18.67% to $3.9 million in 2024, then increased by 7.48% to $4.2 million in 2025, then retreated by 1.19% to $4.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.2 million (Q1 2026), $4.2 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.